Related references
Note: Only part of the references are listed.α-Tetralone derivatives as inhibitors of monoamine oxidase
Lesetja J. Legoabe et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Hydrogen Peroxide Produced by Mitochondrial Monoamine Oxidase Catalysis: Biological Implications
Dale E. Edmondson
CURRENT PHARMACEUTICAL DESIGN (2014)
Monoamine oxidases as sources of oxidants in the heart
Nina Kaludercic et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2014)
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release
John P. M. Finberg
PHARMACOLOGY & THERAPEUTICS (2014)
A neuroscientific update on monoamine oxidase and its inhibitors
Thomas L. Schwartz
CNS SPECTRUMS (2013)
Inhibitor Design for Monoamine Oxidases
Rona R. Ramsay
CURRENT PHARMACEUTICAL DESIGN (2013)
Monoamine Oxidases: The Biochemistry of the Proteins As Targets in Medicinal Chemistry and Drug Discovery
Rona R. Ramsay
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2013)
The interactions of caffeine with monoamine oxidase
Anel Petzer et al.
LIFE SCIENCES (2013)
Depression in Parkinson's disease: diagnosis and treatment
Flavio Henrique de Rezende Costa et al.
ARQUIVOS DE NEURO-PSIQUIATRIA (2012)
The Inhibition of Monoamine Oxidase by 8-(2-Phenoxyethoxy)Caffeine Analogues
B. Strydom et al.
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH (2012)
Opportunities for reversible inhibitors of monoamine oxidase-A (RIMAs) in the treatment of depression
Christopher T. Lum et al.
CNS SPECTRUMS (2012)
Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives
Lesetja J. Legoabe et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2012)
Safety of Selegiline Transdermal System in Clinical Practice: Analysis of Adverse Events From Postmarketing Exposures
Chi-Un Pae et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase
Anel Petzer et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2012)
From depression to neurodegeneration and heart failure: re-examining the potential of MAO inhibitors
Spyros N. Deftereos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2012)
Synthesis and inhibition study of monoamine oxidase, indoleamine 2, 3-dioxygenase and tryptophan 2,3-dioxygenase by 3,8-substituted 5H-indeno[1,2-c]pyridazin-5-one derivatives
J. Reniers et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2011)
An improved approach to steady-state analysis of monoamine oxidases
Rona R. Ramsay et al.
JOURNAL OF NEURAL TRANSMISSION (2011)
Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues
Belinda Strydom et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2010)
Structure of human monoamine oxidase A at 2.2-Å resolution:: The control of opening the entry for substrates/inhibitors
Se-Young Son et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
Hubert H. Fernandez et al.
PHARMACOTHERAPY (2007)
Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs
Claudia Binda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
MBH Youdim et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
The therapeutic potential of monoamine oxidase inhibitors
MBH Youdim et al.
NATURE REVIEWS NEUROSCIENCE (2006)
Binding of rasagiline-related inhibitors to human monoamine oxidases. a kinetic and crystallographic analysis
C Binda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening
L Novaroli et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors
F Hubálek et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Moclobemide: Therapeutic use and clinical studies
U Bonnet
CNS DRUG REVIEWS (2003)
Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation
I Berlin et al.
ADDICTION (2002)
Share Paper
